What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet

Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19 has abated, finds a new report from Citeline.  

Citeline’s annual analysis of completed clinical trials for 2023 reveals a clear break from the COVID-19 pandemic-driven fluctuations seen since 2020. The industry has finally got back where it was at the end of the last decade now that the focus on infectious diseases and vaccines has tapered off and disruptions to other trials have come to an end.

Key Takeaways
  • Nearly 11% more clinical trials completed in 2023 than in 2022.

Citeline’s TrialTrove database recorded 4,295 industry-sponsored trials from Phase I to Phase III/IV that either reached completed status or reported...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.